NEWTON, Mass. — Abcuro, Inc., a clinical-stage biotech company focused on autoimmune diseases and cancer, has appointed Courtney Cupples as Chief Commercial Officer, the company announced Wednesday. Cupples brings over 25 years of global commercial leadership and rare disease launch experience as the company prepares for the potential commercialization of its lead therapeutic candidate, ulviprubart.
Currently in Phase 3 development for the treatment of inclusion body myositis (IBM)—a rare, progressive muscle-wasting disease—ulviprubart could become a first-in-class therapy targeting cytotoxic T cells. Cupples will play a key role in developing the company’s commercial strategy as it nears the pivotal data readout expected in the first half of 2026.
“Courtney has extensive expertise in global commercial strategy and has led several successful orphan drug launches,” said Abcuro CEO Alex Martin. “We’re excited to welcome her to the leadership team as we enter this critical stage of our growth.”
Cupples most recently served as Chief Commercial Officer at Priovant Therapeutics, where she oversaw launch preparations for brepocitinib, an oral therapy targeting severe autoimmune diseases. She previously held leadership roles at Genzyme, Biohaven Pharmaceuticals, and Alexion Pharmaceuticals, where she spearheaded the launch of Soliris® in Latin America and led global franchises for Strensiq® and Kanuma®.
“I’m thrilled to join Abcuro’s team of innovative and passionate individuals working to bring transformative science to patients with IBM,” said Cupples. “I look forward to contributing to this next phase as we prepare for the MUSCLE study data and potential commercialization.”
Cupples holds a Bachelor of Arts in Sociology and Anthropology from Swarthmore College. Her appointment signals Abcuro’s increasing focus on commercialization as it transitions from clinical development to potential market entry.
